Vor Biopharma Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
On March 26, 2026, Vor Biopharma sold 5,338,078 shares of common stock to TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. for aggregate proceeds of $74,999,995.90 at $14.05 per share. The investors received registration rights to resell shares; Company must file registration statement within 30 days and achieve effectiveness within 60 days, with liquidated damages of 1% per 30-day blackout period (capped at 5% aggregate).
Why this rating
~$75M raise is material—nearly equal to company's $76M market cap—providing substantial runway. Reprices equity upward. Registration obligations and liquidated damages clauses are manageable. Positive near-term but moderate dilution.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.